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bstract
The protective capabilities of three Leishmania recombinant proteins – histone 1 (H1) and hydrophilic acylated surface protein B1 (HASPB1)
mmunized singly, or together as a protein cocktail vaccine with MontanideTM, and the polyprotein MML immunized with MPL®-SE adjuvant
were assessed in beagle dogs. Clinical examination of the dogs was carried out periodically under blinded conditions and the condition of
he dogs defined as asymptomatic or symptomatic. At the end of the trial, we were able to confirm that following infection with L. infantum
romastigotes, five out of eight dogs immunized with H1 MontanideTM, and four out of eight dogs immunized with either the combination
f HASPB1 with MontanideTM or the combination of H1 + HASPB1 with MontanideTM, remained free of clinical signs, compared with
®wo out of seven dogs immunized with the polyprotein MML and adjuvant MPL -SE, and two out of eight dogs in the control group. The
esults demonstrate that HASPB1 and H1 antigens in combination with MontanideTM were able to induce partial protection against canine
eishmaniasis, even under extreme experimental challenge conditions.
2007 Elsevier Ltd.
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. Introduction
Leishmania are protozoan parasites that cause a wide
pectrum of human diseases from self-limiting cutaneous
eishmaniasis to potentially fatal visceral infection. Zoonotic
isceral leishmaniasis (ZVL) caused by Leishmania infan-
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Open access under CC BY license.um is an emerging veterinary and public health problem
n endemic areas of the Mediterranean basin, extending to
he middle East, Asia and South America (L. chagasi) [1,2].
ransmission between dogs, or from dogs to man occurs by
he bite of a phlebotomine sand fly. Pet dogs are the princi-
le reservoir for maintaining the domestic cycle of parasites
hilst stray dogs and wild canids maintain the peridomestic
ycle and appear to spread the disease [3]. Epidemiologi-
al surveys have demonstrated high infection rates of dogs
n endemic areas (67% in Majorca, Spain), even though
eishmania infection remains subclinical in most cases
4,5].Current strategies to control ZVL are essentially ineffec-
ive. The treatment of dogs with drugs such as antimonials or
mphotericin B has a high cost and low efficacy, with relapses
ccurring in the majority of dogs. A significant proportion
cine 25
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f these dogs, although clinically asymptomatic, are also
ble to transmit parasites to the sand fly [6,7]. Furthermore,
uccessive treatment following relapse could introduce resis-
ant strains of parasites, thus representing a clear risk to
uman health [8]. The mass culling of infected dogs has had
ixed results in reducing human leishmaniasis prevalence
n endemic areas and is generally not accepted for ethical
nd social reasons [9–12]. Therefore, the development of
protective vaccine in dogs would be an important tool to
fficiently control canine visceral leishmaniasis (CVL) thus
educing the chances of infectivity to sand fly vectors and
onsequently the transmission to humans.
In recent years, efforts have been made by several differ-
nt groups to develop vaccines against canine leishmaniasis.
illed Leishmania antigen plus bacillus Calmette-Gue´rin
BCG) adjuvant [13] were used in phase I and II clinical trials
n Brazil with high protection rates, however, this formulation
ailed to detect any significant differences between vaccine
nd placebo groups in phase III field assays [14]. The gly-
oprotein enriched fucose mannose ligand (FML) vaccine of
. donovani in combination with QuilA adjuvant, was shown
o elicit a protective effect in the field [15] and to further
lock transmission by keeping the vaccinated dogs free of
arasites [16]. More recently, an experimental vaccine trial
sing L. infantum antigen proteins excreted – secreted from
romastigotes (LiEASAP), together with muramyl dipeptide
MDP) adjuvant, was successful in preventing L. infantum
nfection [17]. The use of a more defined Leishmania anti-
en as vaccine candidate included such preparations as the
ecombinant multi-component antigenic protein, named Q,
hich when formulated with BCG led to 90% protection
n immunized dogs under experimental infection conditions.
owever, the absence of an adjuvant control group in this
tudy undermined the significance of antigen specific protec-
ion [18]. Defined antigens in the form of DNA have also been
rialed with some success [19,20]. In the latter study, a cock-
ail consisting of cysteine proteinase type I (CPB) and type II
CPA) antigens from L. infantum were used in a heterologous
rime-boost (DNA-protein) vaccination against experimental
anine leishmaniasis. However, vaccination with a recom-
inant L.infantum CPA and CPB preparation using canine
L-12 as adjuvant did not protect dogs from infectious chal-
enge [21]. The first defined recombinant vaccine antigen to
ndergo phase III field assays was recently described [22].
he antigen used was the polyprotein MML, also known
s Leish111f [23,24]. This antigen when used in combina-
ion with either MPL®-SE or Adjuprime adjuvants failed to
rotect dogs from natural Leishmania infection or disease
rogression.
In this work, we examined the protective capability of
he recombinant histone H1 (H1) and hydrophilic acylated
urface protein B1 (HASPB1) as novel antigens in a vac-
ine against experimental canine leishmaniais. Both H1 and
ASPB1 have previously been shown to be protective in the
ouse [25,26] and for H1, in a monkey model [27] of leish-
aniasis. We therefore examined the immunogenicity and
b
b
r(2007) 5290–5300 5291
fficacy of L. infantum H1 and L. donovani HASPB1 anti-
ens in combination with MontanideTM adjuvant singly, or
ogether as a protein cocktail vaccine, in dogs under high dose
xperimental challenge conditions. In addition, the previ-
usly examined MML polyprotein [22] in combination with
PL®-SE adjuvant was included in this trial. Clinical, par-
sitological and immunological examination of the animals
ere carried out for a period of 64 weeks following infection.
. Materials and methods
.1. Parasites
The L. infantum strain JPC (MCAN/ES/98/LLM-722)
as isolated from the spleen of a dog with patent canine
eishmaniasis. Parasites were grown in NNN medium for 2
eeks and sub-cultured to complete RPMI-medium (RPMI
640, Gibco, Paisley, UK) supplemented with 100 UI/ml of
enicillin, 100g/ml of streptomycin, 2 mM l-glutamine,
× 10−5 M 2-mercaptoethanol and 10% heat inactivated
oetal calf serum (Biological Industries, Israel). Parasites
ere further cultured in acidified complete RPMI-medium
pH 5.5 at 27 ◦C) for 3 days to promote metacyclogenesis. The
irulence and infectiveness of this strain has been confirmed
n dogs by others [28].
.2. Vaccine antigens
The L. infantum histone H1 (DQ232891) was cloned into
he pGEX-KG vector (Amersham Biosciences), expressed in
scherichia coli and purified using GST affinity resin (Amer-
ham Biosciences), as previously described [25]. HASPB1
AJ011810) was cloned into the pET15b vector, expressed
n E. coli and initially purified on a Ni-NTA resin then fur-
her purified using an Anion exchange column (Amersham
iosciences). The histone H1 and HASPB1 proteins were
urified from endotoxins under pyrogenic free conditions in
× PBS on a Superose 12 column (Amersham Biosciences).
ndotoxin levels were determined using a Chromagenic LAL
it (Bio-Whitttaker) and ensured to be below 5 EU/mg. The
nal concentration and purity of proteins was determined
y SDS-PAGE, RP-HPLC (Waters Alliance) and MALDI-
OF mass spectrometry (Perkin-Elmer Biosystems). One
illigram samples were lyophilized in 1× PBS + 5% manni-
ol for histone H1. HASPB1 was prepared as 1 mg/ml aliquots
n 1× PBS. The polyprotein MML was prepared by Novartis
nimal Vaccines Ltd. (Braintree, UK) following previously
eported procedures [24].
.3. AnimalsForty eight beagle dogs were used for this study. Animals
etween 8 months and 3 years old were purchased from dog
reeders in different regions of Spain. All dogs had received
outine vaccinations. Absence of Leishmania infection was
5 ccine 25
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onfirmed prior to commencement of the study in all the
nimals by lack of specific serum antibodies to L. infan-
um as measured by indirect immunofluorescent antibody test
IFAT) as previously described [7] and by ELISA. Culture
nd PCR analysis of different tissues (skin, peripheral blood,
one marrow, and popliteal lymph node) were also negative in
ll cases and specific lymphoproliferative response to leish-
anial antigens was not detected following in vitro culture
f peripheral blood mononuclear cells (PBMCs). Dogs were
ept in our own facilities at the National Centre for Micro-
iology, Majadahonda (Madrid), under constant veterinary
are.
.4. Immunization and experimental infection
Dogs were distributed into seven groups (eight animals
er vaccine and control groups and four animals per adjuvant
roup) taking into consideration sex, weight and age. Sex
atio (m/f) was 4/4 or 2/2 in all groups except for one group
here it was 1/3. Mean age of the animals for each group
aried between 14.7 and 18 months, and the mean weight of
he animals for each group ranged from 9.5 to 11.7 kg. No
tatistically significant differences exist between the groups
ue to mean age or weight (p < 0.05).
Dogs received three intradermal doses (dorsum;
ml/dose) of each vaccine formulation for a period of 3
onths. On day 0, dogs from group HASPB1 and group
1 received 100g of HASPB1 or histone H1 protein. On
ays 30 and 60 the dogs received 45g of either protein.
ogs in group HASPB1 + H1 received a cocktail of histone
1 and HASPB1 (100g each) at day 0, and 45g of each
rotein on days 30 and 60. The adjuvant used for dogs in
roups HASPB1, H1 and HASPB1 + H1 was MontanideTM
SA 720 (70% formulation, according to manufacturer’s
nstructions, SEPPIC), given on days 0 and 30. The final
mmunization on day 60 for groups HASPB1, H1, and
ASPB1 + H1 was prepared in the absence of adjuvant
o avoid side effects observed following the second dose.
hese dogs were thus immunized with proteins formulated
n 1× PBS for the third vaccination. Animals from group
ontanide were inoculated with MontanideTM adjuvant
nly on days 0 and 30. On day 60 these dogs were inoculated
ith 1 ml of PBS. Dogs from group MML received three
oses of 45g of MML plus a 50g/dose of MPL®-SE
djuvant on days 0, 30 and 60. Animals from group
PL-SE received the MPL®-SE adjuvant preparation only.
ogs in the positive infection control group received three
oses of 1 ml PBS on days 0, 30 and 60. Forty-five days
ollowing the final immunization, all dogs were infected
ntravenously with 1 × 108 virulent L. infantum promasti-
otes..5. Clinical examination and laboratory analysis
Routine clinical and laboratory evaluation of the animals
as carried out every 4 weeks for a total of 64 weeks. In
w
t
c
o(2007) 5290–5300
ach evaluation dogs were weighed and their general health
tatus was examined. Biological samples were obtained for
aboratory analysis as described below.
.5.1. Clinical examination for symptoms of CVL
Examination of the dogs for endpoint determination of
VL was carried out blind by an independent clinical veteri-
arian at weeks 16, 34, 42, 52, 57 and 62 post-challenge.
he condition of the dogs was defined according to the
xternal signs of canine leishmaniasis as asymptomatic (no
xternal sign of canine leishmaniasis), or symptomatic when
he dogs showed one or more external clinical signs of
VL including, lymphadenopathy, onychogryphosis, alope-
ia, cutaneous lesions, weight loss or keratoconjuncti-
itis.
.5.2. Haematology and biochemistry
Blood samples taken from the jugular vein were kept in
a2+-EDTA tubes and were analyzed for hematocrit, total
rythrocytes, leukocytes, lymphocytes, and platelet counts
y an automated blood cell counter (Vet ABC, Scil, France).
erum levels of alanine aminotransferase (ALT), aspartate
minotransferase (AST), blood urea nitrogen (BUN), crea-
inine, alkaline phosphatase (alk. phosph.), globlulines and
otal proteins were determined by a biochemistry serum ana-
yzer (IDDEX, Netherlands).
.5.3. ELISA
Serum levels of specific antibodies to L. infantum SLA
29], rK39 [30], HASPB1, histone H1 or MML were analyzed
y ELISA. Microtiter plate wells were coated with either SLA
1g), rK39 (50 ng), HASPB1 (50 ng), histone H1 (200 ng)
r MML (50 ng). Each serum sample was diluted 1/100
nd tested in duplicate. Bound antibody was detected with
rotein-A-conjugated horseradish peroxidase. The optimum
ilutions for the test sera and conjugates were determined by
hecker-board titration. The optical density of the wells was
ead at 405 nm.
.5.4. Cell isolation and proliferation assay
PBMCs were isolated from heparinized blood samples
sing standard Ficoll-hypaque gradient centrifugation (Lym-
hocyte Isolation Solution, RAFER, Spain) and washed twice
n 1× PBS. PBMCs at 2.5 × 105 cells/well were cultured in
at-bottomed 96-well plates at 37 ◦C for 5 days in complete
edium (RPMI 1640 supplemented with 100 U/ml penicillin,
00g/ml streptomycin, 2 mM l-glutamine, 25 mM HEPES
nd 10% heat-inactivated foetal calf serum). The cells were
ncubated in triplicate with either complete media (blank),
0g/ml soluble leishmanial antigen (SLA) or 10g/ml con-ith 1Ci of methyl-3H thymidine and counted in a scintilla-
ion counter. Results were expressed as stimulation index (net
ounts per minute of stimulated cells/net counts per minute
f unstimulated cells).
cine 25
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SE, three out of four (75%) and four out of four (100%)
animals, respectively, presented clinical manifestations of
leishmaniasis. Five out of seven (71%) animals from group
MML showed symptoms throughout the trial. In groups
Fig. 1. Number of asymptomatic dogs in each group following challenge
infection. Clinical examination for symptoms of CVL (lymphoadenopathy,J. Moreno et al. / Vac
.6. Parasitological analysis
Presence of the parasite was determined by in vitro culture
nd PCR of bone marrow and lymph node aspirates taken
very 4 weeks post-challenge. All samples were diluted in
00l of PBS.
.6.1. In vitro culture
One hundred microliters of the diluted samples were
ultured in di-phasic blood-agar NNN medium, maintained
t 27 ◦C and examined for promastigote forms under light
icroscopy every week. The original cultures were subcul-
ured into fresh medium every week for up to 4 weeks. The
ample was considered negative if there were no parasites
bserved at the end of this period.
.6.2. DNA extraction and diagnostic PCR
One hundred microliters of bone marrow, lymph node,
kin and PBMC samples were used for DNA extraction.
hree hundred microliters of NET10 buffer and 40l
f 10% SDS were added to each sample, incubated at
0 ◦C for 1 h and purified using phenol/chloroform extrac-
ion and ethanol precipitation. DNA was resuspended in
00l of distilled water. Leishmania specific nested PCR
as performed to detect leishmanial DNA on the dif-
erent biopsies. Ten microliters of DNA was used as
emplate. In the first amplification 15 pmol of the Kinetoplas-
ida specific primers R221 (GGTTCCTTTCCTGATTTACG)
nd R332 (GGCCGGTAAAGGCCGAATAG), were mixed
ith 0.2 mM deoxynucleoside triphosphates (Amersham
harmacia Biotech, Sweden), 2 mM MgCl2, 5 mM KCl,
5 mM Tris–HCl pH 9.0, 2.0 mM (NH4)2SO4, 0.001%
ovine serum albumin and 1.4 units of Tth DNA poly-
erase (Biotools B&M Laboratories, S.A., Madrid, Spain).
he cycling conditions were 94 ◦C for 5 min followed by
5 cycles of 94 ◦C for 30 s, 60 ◦C for 30 s, 72 ◦C for
0 s, followed by a final extension at 72 ◦C for 10 min.
amples revealing a 603 bp PCR product were scored
s positive for Leishmania DNA. Nested PCR (second
mplification) was performed using the amplified prod-
cts from the first reaction together with above mentioned
aster mix and the Leishmania-specific primers (3 pmol
ach) R223 (TCCCATCGCAACCTCGGTT) and R333
UGCGGGCGCGGTGCTG′. Tth DNA polymerase (0.7
nits) was added and the annealing temperature raised to
5 ◦C. Positive samples yielded a PCR product of 358 base
airs [31].
.7. Statistical analysisDifferences between the groups using the mean
alue ± S.D. was evaluated by Student’s t-test. Differences
ver time for a given group were evaluated by Student’s t-test
ith matched data.
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. Results
.1. Adverse reactions upon vaccination
The different vaccines were well tolerated and only a local
eaction (skin inflammation) at the point of inoculation was
bserved after the second injection in some dogs from groups
ASPB1, H1, HASPB1 + H1, and Montanide. Considering
hat the adjuvant MontanideTM had been included in the
reparation of immunizations for all these groups, it was not
ncluded in the third inoculation in order to avoid a systemic
eaction. Following the third immunization no local reaction
as observed in the dogs. One animal from group MML
ied after the course of immunizations and prior to chal-
enge. Following autopsy examination, the death was found
o be related to a gut obstruction and not to the vaccination
rocedure. The MML group thus had seven animals for the
emainder of the study.
.2. Clinical manifestations
Following high dose experimental infection, non-
accinated control dogs, adjuvant inoculated dogs (groups
ontanide and MPL-SE) and antigen plus adjuvant vacci-
ated dogs (groups HASPB1, H1, HASPB1 + H1 and MML)
ere periodically checked by an independent experienced
linical veterinarian for the appearance of external clini-
al manifestations of CVL. The number of dogs in each
roup that developed patent symptoms of leishmaniasis such
s lymphadenopathy, onychogryphosis, alopecia, cutaneous
esions, weight loss and keratoconjunctivitis post-challenge
nfection is shown in Fig. 1. In the control group, six out
f eight animals (75%) developed patent clinical symptoms
f leishmaniasis. In adjuvant groups Montanide and MPL-nychogryphosis, alopecia, cutaneous lesions, weight loss or keratoconjunc-
ivitis) was carried out at weeks 16, 34, 42, 52, 57 and 62 post-challenge
indicated by arrows). The initial number of animals for all groups was 8
xcept for the MML group where the initial number was 7, and the Montanide
nd MPL-SE groups where the starting number of animals was 4.
5 ccine 25 (2007) 5290–5300
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Fig. 2. Mean weight of each group of dogs during the study. Data are shown
as mean weight ± S.D. in kg. Weights at preimmunization (week −16), pos-
timmunization pre-challenge (week 0), and post-challenge (weeks 16, 32, 48
and 64) are shown. Error bars represent the standard deviation for each group.
No statistically significant differences were observed between the groups at
the different time points. Statistical analysis using the Student’s t-test with
matched data indicated that there was a decrease of the mean weights for a
particular group at the end of the study (week 64) when compared with the
mean weight recorded in previous weeks. (a) Significant (p < 0.05) decrease
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ASPB1 and HASPB1 + H1, four out of eight dogs (50%)
ere symptomatic, and in group H1, only three out of eight
37.5%) animals developed the disease. Symptoms in the
ogs appeared from week 32 after experimental infection,
xcept for one dog from group HASPB1 + H1 that showed
linical signs of canine leishmaniasis 16 weeks after chal-
enge.
Presence or absence of specific symptoms did not correlate
ith any specific experimental vaccine group and was inde-
endent of sex, age and starting weight of the animals. The
requency of clinical symptoms recorded for each group is
howed in Table 1. The severity and duration of these clinical
anifestations varied between dogs. Some animals presented
progressive polysymptomatic form of the disease, show-
ng multiple and severe symptoms that required, in some
ases, that the animal be killed. Other dogs presented few
nd mild symptoms and remained olygosymptomatic during
he course of the study. At each follow up, the weight of the
ogs was recorded. Weight loss is a characteristic symptom
f CVL. In this study, most of the symptomatic animals lost
eight from week 32 until the end of the trial. Decrease of
he mean weight between week 32 or 48 and week 64 was
bserved in groups HASPB1, H1, HASPB1 + H1, Montanide
nd control, but differences were only significant in dogs from
roups HASPB1, Montanide and control (Fig. 2).
.3. Haematology and serum biochemistryDetermination of the haematological values showed that
xperimental infection induced a progressive decrease in
he mean number of total white blood cells, lympho-
e
u
l
c
able 1
requency of clinical symptoms
linical symptoms of CVL HASPB1 H1 HASPB1 +
ymphadenopathy 37.5 25 50
lopecia 37.5 50 62.5
utaneous lesions 37.5 25 37.5
nychogryphosis 50 25 37.5
eratoconjuctivitis 37.5 37.5 50
eight loss 37.5 25 25
alues represent the percentage of animals in each group that showed the specific s
able 2
aematological analysis
roup Haematological values
Leucocytes Lymphocytes
Week 0 Week 64 Week 0 Week 6
ASPB1 14.3 ± 3.2 10.0 ± 4.7* 2.10 ± 0.82 1.09 ±
1 13.7 ± 2.3 9.7 ± 3.8* 1.80 ± 0.39 1.55 ±
ASPB1 + H1 11.3 ± 1.9 6.8 ± 3.3* 2.54 ± 0.52 1.19 ±
ontanide 12.0 ± 4.4 6.8 ± 3.2 2.02 ± 1.28 0.78 ±
ML 11.6 ± 2.6 5.5 ± 2.6* 1.94 ± 0.72 0.78 ±
PL-SE 10.5 ± 1.0 8.0 ± 4.0 1.57 ± 0.58 1.8 ±
ontrol 13.5 ± 2.4 7.2 ± 3.5* 2.26 ± 0.69 0.98 ±
alues are shown for each group at pre-challenge (week 0) and at the end of the stu
* Statistically significant (p < 0.05) differences between the value at pre-challengf the mean weight in comparison to week 32, (b) significant (p < 0.05)
ecrease of the mean weight in comparison to week 48, and (c) significant
p < 0.05) decrease of the mean weight in comparison to week 32 and 48.
ytes, erythrocytes and platelets (Table 2). Differences in
hese cell counts between pre-challenge and the end of the
og trial were statistically significant in groups HASPB1,
ASPB1 + H1, MML and control. Group H1 showed sig-
ificant differences only in the case of leucocytes and
rythrocytes. Both groups (Montanide and MPL-SE) inoc-
lated with adjuvant only, also showed a decrease in the
evels of the different cell counts. Differences between pre-
hallenge and the last follow up were only significant,
H1 Montanide MML MPL Control
50 43 50 62.5
25 71.4 100 87.5
25 28.5 75 62.5
50 57 50 62.5
50 43 75 50
50 28.5 50 62.5
ymptom of CVL at week 64.
Erythrocytes Platelets
4 Week 0 Week 64 Week 0 Week 64
0.45* 7.08 ± 0.37 4.68 ± 1.02* 301 ± 62 203 ± 94*
0.82 6.35 ± 0.52 5.01 ± 1.01* 295 ± 97 216 ± 188
0.75* 7.62 ± 1.88 4.27 ± 1.38* 367 ± 51 172 ± 92*
0.32 6.63 ± 0.48 4.51 ± 1.88 274 ± 89 169 ± 41*
0.32* 6.94 ± 0.17 3.59 ± 0.92* 353 ± 89 181 ± 80*
0.43 7.08 ± 0.43 5.16 ± 1.23* 316 ± 25 244 ± 162
0.60* 6.91 ± 0.85 4.21 ± 1.07* 273 ± 66 171 ± 59*
dy (week 64).
e (Week 0) and at the end of the trial (Week 64).
J. Moreno et al. / Vaccine 25 (2007) 5290–5300 5295
Table 3
Biochemical analysis
HASPB1 H1 HASPB1 + H1 Montanide MML MPL Control
AST 37.5 50 75 75 57.1 50 62.5
ALT 12.5 12.5 0 25 14.2 0 0
Alkaline phosphatase 12.5 12.5 0 25 14.2 0 0
BUN 0 12.5 12.5 0 14.2 0 12.5
Creatinine 0 0 0 0 0 0 12.5
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slobulins 50 62.5 62.5
otal proteins 37.5 37.5 37.5
alues represent the percentage of animals in each group that showed serum
owever, for platelet (group Montanide) and erythrocyte
ounts (group MPL-SE). This lack of difference in cell counts
or the adjuvant groups is likely due to the small number of
nimals in these groups.
Serum biochemistry analysis throughout the experiment
evealed that serum levels of creatinine and BUN remained
ithin normal levels (0.5–1.8 mg/dl and 7.0–27.0 mg/dl,
espectively) in most of the animals (Table 3). Serum lev-
ls of alkaline phosphatase (normal range 23–212 U/l) and
LT (normal range 10–100 U/l) were both increased in one
ymptomatic dog from groups HASPB1, H1, Montanide and
ML. Alterations in the serum levels of AST (normal range
–50 U/l), globulins (normal range 2.5–4.5 g/dl) and total
roteins (normal range 5.2–8.2 g/dl) were observed in those
nimals with multiple patent clinical symptoms of leishmani-
sis, independent of the group. Levels of AST were increased
ver 50 U/l in 84% of the symptomatic animals, while serum
lobulin levels exceeded the normal range in 92.4% of the
ymptomatic cases.
t
o
c
l
able 4
n vitro parasite detection
Week HASPB1 H1 HASPB
one marrow
Culture 0 0 0 0
16 50 37.5 87.5
32 75 50 75
48 37.5 25 37.5
64 37.5 37.5 62.5
CR 0 0 0 0
16 75 50 87.5
32 75 50 75
48 75 25 75
64 62.5 37.5 75
ymph node
Culture 0 0 0 0
16 62.5 37.5 75
32 62.5 62.5 87.5
48 75 50 62.5
64 75 50 37.5
CR 0 0 0 0
16 62.5 75 75
32 50 37.5 50
48 25 37.5 50
64 62.5 62.5 62.5
alues represent the percentage of animals in each group that presented positive
amples prior to the experimental infection (week 0) and at weeks 16, 32, 48 and 675 57.1 75 50
75 14.2 75 12.5
of the different biochemical parameters that exceeded the normal level.
.4. Parasite detection
The presence of L. infantum parasites was confirmed in
one marrow and lymph node aspirates by culture in NNN
iphasic medium and by PCR. Both techniques confirmed the
resence of parasites in these target organs from week 4 after
hallenge. The percentage of L. infantum-positive animals in
he different groups of dogs throughout the study is shown in
able 4.
For groups HASPB1, Montanide, MML and MPL-SE, the
ercentage of bone marrow parasite positive animals was sim-
lar to that of the control group for the duration of the study.
roup HASPB1 + H1 presented higher percentages than the
ontrol group, whilst group H1 showed a lower percentage.
here were no clear differences in the percentage of animalshat were lymph node parasite positive by PCR. In the case
f cultured lymph nodes, group MML showed higher per-
entages than the control group, while group H1 presented a
ower proportion of animals that were positive.
1 + H1 Montanide MML MPL-SE Control
0 0 0 0
50 42.8 75 75
75 57.1 50 75
50 57.1 50 37.5
100 42.8 50 37.5
0 0 0 0
75 57.1 75 75
50 42.8 50 62.5
25 57.1 75 37.5
75 57.1 50 25
0 0 0 0
50 85.7 75 62.5
75 85.7 50 75
50 71.4 100 62.5
25 71.4 50 62.5
0 0 0 0
75 85.7 75 75
50 57.1 50 50
50 28.5 50 25
50 71.4 75 25
parasite detection by PCR and culture for bone marrow and lymph node
4 post-challenge.
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.5. Immunological response
Specific antibody responses to the antigens used as vac-
ines was also assessed. Levels of specific serum antibodies
o HASPB1, H1 and MML were determined from the
re-immunization stage to the end of the study (Fig. 3).
fter immunization, total IgG titers against the different
ntigens were detectable in all antigen immunized groups
HASPB1, H1, HASPB1 + H1 and MML). In the case of
roups HASPB1, H1 and HASPB1 + H1, the first immuniza-
ion induced high levels of specific antibodies against the
ntigens that decreased after the second and third immuniza-
ion (Fig. 3C and D). The group vaccinated with the MML
ntigen, presented a progressive increase in levels of specific
ntibodies following each immunization (Fig. 3E).
Immunoglobulin titers against crude soluble leishmania
ntigens (SLA) were detectable in all seven groups of dogs
l
i
l
c
ig. 3. Mean serum levels of specific antibodies. Serum levels of specific antibod
ML (E) were measured during the study by ELISA. Week −14 corresponds to
orrespond to serum antibody levels after the first, second and third immunization. W
ere measured at 405 nm. Error bars represent the standard deviation for each grou(2007) 5290–5300
rom the time of the second follow up. Mean antibody levels
or each group increased gradually until weeks 32–36, and
hen remained high until the end of the study. No significant
ifferences were observed between the mean absorbance of
he groups (Fig. 3A). In all experimental groups, symptomatic
nimals showed the highest levels of anti-SLA serum antibod-
es while in asymptomatic dogs these levels were moderate.
imilar results were obtained for antibodies to the recombi-
ant protein K39 from L. chagasi (Fig. 3B).
After challenge, mean antibody titres against histone H1
ncreased slightly in those groups vaccinated with this anti-
en (groups H1 and HASPB1 + H1) and around week 24,
ecreased to remain low until the end of the study. The serum
evels of anti-H1 antibodies were higher in those animals
mmunized with histone H1 that became symptomatic for
eishmaniasis than in those that remained asymptomatic. The
ontrol group and Montanide adjuvant groups, showed low
ies to the antigens SLA (A), rK39 (B), histone H1 (C), HASPB1 (D), and
serum levels prior to the immunization process. Weeks −10, −6 and 0,
eek 0 also corresponds to the time of experimental infection. OD readings
p.
J. Moreno et al. / Vaccine 25 (2007) 5290–5300 5297
Table 5
Lymphoproliferative response
HASPB1 H1 HASPB1 + H1 Montanide MML MPL Control
Week 0
SLA 1.12 ± 0.8 1.24 ± 0.3 0.97 ± 0.3 1.16 ± 0.4 1.22 ± 0.6 0.98 ± 0.2 1.27 ± 0.4
ConA 7.32 ± 3.6 7.67 ± 2.7 8.17 ± 3.2 8.18 ± 1.8 7.62 ± 2.0 7.42 ± 2.28 8.50 ± 2.8
Week 8
SLA 0.97 ± 0.1 1.39 ± 0.4 1.00 ± 0.4 1.30 ± 0.3 1.33 ± 0.4 1.18 ± 0.4 1.07 ± 0.33
ConA 6.51 ± 4.0 7.20 ± 2.8 12.12 ± 10.5 14.73 ± 11.7 10.97 ± 9.9 18.0 ± 5.8 10.2 ± 6.1
Week 48
SLA 1.00 ± 0.3 1.02 ± 0.5 1.32 ± 0.9 1.12 ± 0.39 0.94 ± 0.5 1.13 ± 0.3 1.28 ± 0.2
ConA 2.59 ± 1.0 4.97 ± 2.9 2.88 ± 1.16 6.31 ± 2.3 3.9 ± 1.1 3.81 ± 0.1 3.45 ± 0.9
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whe results are expressed as the mean stimulation index ± S.D. Lymphopro
nd 48 after experimental infection.
evels of H1 specific antibodies throughout the experiment
Fig. 3C).
HASPB1 vaccinated groups (HASPB1 and HASPB1 +
1) showed a sharp increase in mean antigen specific anti-
ody levels following challenge and these remained elevated
ntil the end of the study. High titres of anti-HASPB1 anti-
odies were found in both symptomatic and asymptomatic
ogs. This increase in specific antibodies for HASPB1 was
lso observed in the control and Montanide groups, which
onfirmed that the effect was due to the experimental infec-
ion (Fig. 3D).
Anti-MML titres in the MML group were on average
igh, and steadily increased after experimental infection to
each a peak level at week 32. No differences were found
etween the levels of anti-MML antibodies in symptomatic
nd asymptomatic animals from group MML. The control
nd MPL-SE groups presented titers 12 weeks post-challenge
gainst MML that were induced by the parasite, but such
evels were lower compared to that of group MML (Fig. 3E).
A lymphoproliferative response specific to SLA was not
bserved in any of the animals following immunization, nor
fter challenge (Table 5).
. Discussion
Increasing awareness that the dog represents a key target
n the control of parasite transmission to humans has pro-
oted interest in development of a vaccine against canine
eishmaniasis. This is theoretically feasible, based on the fact
hat there are a large number of infected dogs in endemic
reas amongst whom only a small proportion develop the dis-
ase [32,33], together with evidence that naturally infected
ogs in endemic areas exhibit lymphoproliferative responses
nd develop a positive skin test against Leishmania antigens
34,35]. Furthermore, recent reports on the immunogenic-
ty and efficacy of several vaccines confirm that protection
gainst CVL is possible.
In the present investigation, we tested vaccines against
VL consisting of the recombinant histone H1 [25,27],
ASPB1 [26,36] or MML antigens [22,37]. The histone H1
i
H
t
ne assays were carried out following immunization (week 0) and at weeks 8
nd HASPB1 antigens were examined individually, or as a
ocktail in combination with the adjuvant MontanideTM-ISA
20. The MML polyprotein antigen was formulated with the
PL®-SE adjuvant. The use of an adequate adjuvant nor-
ally constitutes a major aspect in obtaining an efficient
rotocol of immunization. MontanideTMISA 720 is a min-
ral oil based adjuvant that has been used in our previous
tudies in primates [27] and in other trials in dogs [20], with-
ut production of severe adverse reactions. In the present
tudy, all dog groups immunized with MontanideTMISA 720
roduced local skin reactions. Therefore, a more appropri-
te adjuvant such as MontanideTM-ISA563, which does not
ontain mineral oil and is easier to inject, may be safer
or use in veterinary studies. In the case of HASPB1, pro-
ection in mice was achieved in the absence of exogenous
djuvant [26]. However, this unusual attribute of HASPB1
as not tested in the current study. The adjuvant MPL®-SE
sed for the MML vaccine formulation showed no observ-
ble adverse reactions in this study nor in previous studies in
ogs [22].
Clinical follow up of the animals during the study, together
ith laboratory analysis allowed the classification of dogs as
symptomatic or symptomatic and hence defined the differ-
ntial protection capabilities of the vaccine candidates tested.
n terms of clinical manifestations, the percentages of animals
cored symptomatic by the end of the study were lower in the
ntigen immunized groups of dogs (ranging from 37 to 70%
or groups HASPB1, H1, HASPB1 + H1 and MML), than in
ontrol groups immunized with adjuvant only or PBS (from
5 to 100% for groups Montanide, MPL-SE and control).
hese results indicate that the vaccines containing antigen
ere able to induce a variable partial protection against
eishmania infection, although, due to the low number of
nimals per group, it was difficult to establish whether such
ifferences were statistically significant. The highest levels
f protection were obtained in the group of dogs immunized
ith histone H1 alone (group B), with 62.5% showing no clin-cal symptoms. Half (50%) of the animals immunized with
ASPB1, either alone or in combination with H1, were pro-
ected, and 29% of the animals vaccinated with MML showed
o signs of CVL. The vaccine formulation with MML was
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dentical to that used in a previous study in dogs [22], where
t was also observed not to confer protection upon natural
hallenge.
Several physiological, biochemical and haematological
lterations such as weight loss, increased serum globu-
ins, anaemia, leucopenia or lymphopenia, are commonly
bserved in dogs naturally and experimentally infected by
. infantum [38]. In this study, we were able to demonstrate
hat vaccine-induced protection was associated with a reduc-
ion of such parameters. An effective vaccine against CVL
hould allow a normal gain of weight. Significant differ-
nces in weight loss between week 32 and the end of the
tudy were only observed in the control group and the group
mmunized with a mixture of histone H1 and HASPB1 pro-
eins, while significant differences in weight loss between
eek 48 and the end of the study were observed in the Mon-
anide group. The remainder of the animals did not show
ignificant variations of weight over time. Moreover, exper-
mental challenge was able to induce significant decreases
n the levels of leucocytes, lymphocytes, erythrocytes and
latelets in most of the groups, although such alterations
ere not significant in the group of animals immunized
ith histone H1, which supports the higher percentage of
verall protection induced by this antigen. On the other
and, biochemical analysis showed that increased serum
omponent levels are related to the symptomatic condi-
ions of the animal and not to the particular experimental
roup.
It has been demonstrated that the intensity of tissue para-
itism parallels the development of the clinical manifestations
f CVL [38–40]. In the case of animals immunized with
istone H1, fewer had detectable parasites in the bone mar-
ow and lymph node compared with control group, early
fter challenge. The other groups of dogs did not show
his trend. It was previously indicated that polysymptomatic
ogs are more infectious to sand flies than oligosymptomatic
ogs [41]. Thus, the reduction of the parasite burden in the
anine reservoir through vaccination, even if only partial, as
emonstrated here for the histone H1 immunized group, is
f interest as it could potentially lead to reduced zoonotic
ransmission and control of this disease within an endemic
rea.
Immune recognition of the different recombinant proteins
as confirmed by the detection of antigen specific serum anti-
odies. Serological analysis demonstrated that experimental
nfection induced a strong humoral response against the para-
ite antigens SLA and rK39. Interestingly, challenge infection
lso induced an increase in the serum levels of HASPB1
nd MML specific antibodies but not histone H1 specific
ntibodies. Low anti-histone antibody responses have been
bserved in other studies [42]. It is claimed that the best
redictors of infectiousness for CVL are IgG antibody titres
nd clinical disease, demonstrated by a positive correlation
etween anti-leishmania IgG, parasite detection by PCR,
linical disease and infectiousness to sand flies [4,38,43,44].
hus, the low levels of specific antibodies observed in his-
a
F
t(2007) 5290–5300
one H1 immunized animals may be related to their protective
apability.
Interestingly, the humoral response against “pathoanti-
ens” which includes cytoplasmic and nuclear parasite
ntigens such as histones and the proteins that make up the
ML vaccine antigen, namely, LmSTII, LeIF and TSA [45],
s directly related to the pathological alterations observed in
L patients. Presentation of the intracellular molecules is
uggested to occur via cytolysis of amastigotes with the epi-
opes being localized to a region in each specific sequence
hat is unique to Leishmania, but different or absent in the
ost homologous protein [45,46].
Recent results in mice indicate that vaccination against
eishmania is improved when several distinct antigens are
o-administered [23,42,47–51]. However, the results in dogs
sing multi-component antigens appears to have mixed
esults with partial protection observed in some instances
18,20] and no protection in others [21,22]. In the present
tudy the cocktail vaccine consisting of HASPB1 and his-
one H1 antigens or the polyprotein MML vaccine produced
lesser protective effect in dogs than the histone H1 antigen
lone.
The high-dose intra-venous challenge infection used in
his study proved to be a good method to induce patent
VL in 13 out of 16 control animals (including PBS and
djuvant inoculated animals). However, such strong chal-
enge conditions may have overpowered a protective response
resent in the vaccinated animals as previously described in
ther dog vaccine trials [20,21]. When taking into consid-
ration previous attempts of vaccination against CVL, the
revention of severe disease in the majority of animals is
learly difficult to achieve. Dogs are a good model for human
isceral leishmaniasis because the symptoms in dogs are
imilar to those developed in humans [52]. The partial pro-
ection obtained in the present study confirms the capacity of
ecombinant protein vaccination to restrict parasite replica-
ion and control infection even under high dose experimental
hallenge infection. The efficiency of a vaccine against
VL could now be evaluated in natural infection conditions
hich are likely to be less extreme than those used in this
tudy.
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